Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sniper007on Mar 02, 2022 3:01pm
140 Views
Post# 34476209

RE:RE:RE:RE:RE:RE:RE:RE:One or two more things...

RE:RE:RE:RE:RE:RE:RE:RE:One or two more things...No one can argue that Bioasis been an awful investment thus far, cmonreally, but you arguing a future win for Bioasis is impossible, is utter nonsense. You've been provided the information on a silver platter on why future wins are entirely possible, but you continue to push "it's not happened, so it will never happen". That logic is flawed.

We're simply on different sides of the fence, cmonreally.

I'm ok with you not believing the company will not succeed but I'm not continuously spewing my belief that DrDR will produce. I'm just betting she will and defending my belief.

It's just like FTR who keeps spouting "NOTHING" is going on, when there are numerous pharmas that are working with Bioasis and Xb3. To say NOTHING is going on is just false.

I will say that, I agree with JD in that the Prothena and Chiesi deals were garbage, or "AWFUL", as he put it.

I have my doubts as to whether or not DrDR can produce a great deal, but with Shadow Lake on board, I truly hope the crappy deals of the past, are just that, the past.

I had posted about a year ago about how displeased I was with DrDR saying the projected value of Xb3-001 was $300-500 million when Herceptin generates roughly 7 Billion a year. She got some bad intel on that but it's her fault for not understanding the numbers. She's since changed her tune to 3-4 Billion for Xb3-001 (I can't remember the exact numbers offhand).

I hope DrDR sticks to her guns but she's got the LOC and hopefully some milestone payment(s) coming soon. That should buy us some time. She's also got Shadow Lake which I hear is doing a fantastic job. That's ammo in her guns.

We need to be taken seriously, so wait for the right deal, DrDR. 

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse